Clinical Trials Browser

Phase 2 × Colonic Neoplasms × pembrolizumab × Clear all

Colonic Neoplasms

NCT07223424 2026-04-16

PSI-Immune

DermatologicGastrointestinalGenitourinaryGynecologicThoracic

Adenocarcinoma Of Esophagus, Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Carcinoma, Squamous Cell, Uterine Cervical Neoplasms, Colitis, Ulcerative, Colonic Neoplasms, Esophageal Neoplasms, Carcinoma, Hepatocellular, Melanoma

NCT05217446 2026-04-07

SEAMARK

Phase 2 Active not recruiting

107 enrolled

Gastrointestinal

Colonic Neoplasms, Rectal Neoplasms, Colorectal Neoplasms

NCT07409844 2026-02-20

RESET C2

Phase 2 Not yet recruiting

152 enrolled

Gastrointestinal

Colonic Neoplasms

NCT06646445 2025-06-13

PREMICES

Phase 2 Not yet recruiting

60 enrolled

Gastrointestinal

Turcot syndrome, Colonic Neoplasms, Microsatellite Instability

NCT05662527 2024-08-13

RESET-C

Phase 2 Completed

85 enrolled

Gastrointestinal

Colonic Neoplasms

NCT04231526 2024-07-31

Pembrolizumab in Early Stage Colon Cancer

Phase 2 Withdrawn

Gastrointestinal

Colonic Neoplasms

Clinical Trials

NEOPRISM-CRC

PSI-Immune

SEAMARK

RESET C2

PREMICES

RESET-C

Pembrolizumab in Early Stage Colon Cancer